Advertisement

Topics

Latest Biotechnology Products NewsRSS

21:14 EST 18th January 2017 | BioPortfolio

NW Bio Presenting At Phacilitate Immunotherapy World Conference

BETHESDA, Md., Jan. 18, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present at the Phacilitate Immunotherapy World Conference on Thursday, January 19, 201...

Michael J. Hennessy Associates, Inc. Launches New Center for Biosimilars Website

The new Center for Biosimilars website will include news, videos, conference coverage, continuing education, and interviews with key experts and stakeholders. Cranbury, NJ (PRWEB) January 18, 2017 Michael J. Hennessy Associates, Inc., (MJH), a full-service health care communications company, launched a new website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. Pres...

Kythera Biopharmaceuticals Inc KYTH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryKythera Biopharmaceuticals Inc Kythera, a subsidiary of Allergan Plc is a clinicalstage biopharmaceutical company that discovers, develops and commercializes medical aesthetics products. The company's product candidate, ATX101 is a patented formulation of deoxycholic acid in injectable form in late stage clinical development for submental fullness. It has development programs in the areas o...

AbbVie’s Humira IP strategy having ‘chilling effect on competition,’ UK judge

A UK judge says a vexatious litigation strategy is staving off Humira biosimilars, but AbbVie is “playing by the rules and incurring the costs of doing so,” according to an IP lawyer.

Cantab Biopharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryCantab Biopharmaceuticals Ltd CBL, subsidiary of Celtic Pharma Holdings LP is a biopharmaceutical company that discovers and develops a range of drugs and drug formulations for the healthcare industry. The company's activities include biopharmaceutical discovery, process development and GMP manufacturing to expedite the development of biosuperiors from inception through clinical developmen...

Asterias Biotherapeutics Announces Conference Call To Discuss 6-Month Efficacy Data From AST-OPC1 SCiStar Study

  Life Sciences Jobs   ...

NIAID Awards Paragon Bioservices a Multiple Award IDIQ Contract valued up to $159M for Preclinical Drug Development Services

BALTIMORE, Jan. 17, 2017 /PRNewswire/ -- Paragon Bioservices received a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract to provide product development services for a variety of National Institute of Allergy and Infectious Diseases (NIAID) medical product development activities. The IDIQ mechanism will allow Paragon to compete within a contractor pool for task order aw...

FDA guidance recommends distinct names, suffixes for biosimilars

The FDA has released its final guidance for the naming of biological products, which recommends distinct names and suffixes for both biosimilars and reference products, according to a press release from the American College of Rheumatology.“The American College of Rheumatology [ACR] has long advocated for explicit guidance about distinct names and suffixes for biosimilars in order to prevent ina...

MilliporeSigma Opens Production Facility Exclusively for Meglumine in Spain

- Regulatory compliant, FDA-audited facility based in Mollet des Vallès, Spain - The only facility in Europe solely dedicated to meglumine production BILLERICA, Mass., Jan. 17, 2017 /PRNewswire/ -- MilliporeSigma, a leading science and technology company, today announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved ...

Alder Biopharmaceuticals Inc ALDR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryAlder Biopharmaceuticals Inc Alder develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushing's disease and autoimmune and inflammatory diseases. The company offers technologies such as the antibody selection ABS system and novel Mab Xpress antibody production system. Its pipeline products include ALD403, ALD1613 and Clazakizumab Alder's ALD403 is...

Biocatalysis Biocatalysts Market By Type Hydrolases, Oxidoreductases, Transferases, And Others, Application Food Beverages, Cleaning Agents, Agriculture Feed, Biofuel Production, Biopharmaceuticals, And Others, And Geography Forecast Till 2019 Prices

The biocatalysts market was estimated around 81 kilo tons in 2013, with the high share of around 70% held by North America and Europe together. The global biocatalysts market by volume is projected to grow at a CAGR of 5.5% from 2014 to 2019. The high growth is forecasted to be in the RoW due to rise of end industries such as biofuel production, agriculture feed, food and beverages in the region....

Synergys Biotherapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummarySynergys Biotherapeutics Inc Synergys Biotherapeutics is an early stage company that develops targeted antibody biotherapeutic products for treatment of various solid tumors. The company's pipeline portfolio encompasses a multifunctional antivasculogenic antibody fusion molecule for the treatment of Triple Negative Breast Cancer TNBC; a therapeutic targeted for ovarian cancer and for HER2+ ...

FDA guidance recommends distinct names suffixes for biosimilars

The FDA has released its final guidance for the naming of biological products, which recommends distinct names and suffixes for both biosimilars and reference products, according to a press release from the American College of Rheumatology.“The American College of Rheumatology [ACR] has long advocated for explicit guidance about distinct names and suffixes for biosimilars in order to prevent ina...

Week of Jan. 16: What to watch for in biopharma

We’re facing a bit of an anticlimax this week, now that J.P. Morgan has come and gone. But many happenings await us in the wide world of biopharmaceuticals.

Horizon Extends CRISPR License with ERS Genomics and Inks Partnership with Solentim

Horizon Discovery extended its existing CRISPR licence with ERS Genomics, to give Horizon rights to use CRISPR-edited cell lines for the GMP manufacture of biotherapeutics. The Cambridge, U.K.-based company in parallel reported a two-year collaboration with cell line development specialist, Solentim, to generate an automated manufacturing platform for mammalian cell genome editing. Horizon alr...

Northwest Biotherapeutics Inc NWBO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryNorthwest Biotherapeutics Inc NW Bio is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer in an effective way without toxicities associated with the normal chemotherapy drugs. Using its proprietary technology platform, DCVax, the company developed a robust pipeline of therapeutic product candidates. DCVax is a personalized immune the...

Keryx Biopharmaceuticals, Inc. (KERX) Raised to Neutral at Citigroup Inc.

The brokerage presently has a $7.00 target price on the biopharmaceutical company's stock. Citigroup Inc.'s target price would indicate a potential upside of 11.82% from the stock's current price.

Biosimilars Market by Product Recombinant NonGlycosylated Proteins Insulin, Filgrastim, Interferons, rHGH, Glycosylated Monoclonal Antibodies, EPO, Peptides Glucagon, Calcitonin Application Oncology, Blood Disorders Global Forecast to 2020 Prices from U

Various factors have contributed to the rise in demand for biopharmaceutical products such as biologics and biosimilars. Some of these factors include the rising pressure to reduce healthcare expenditure, growing demand for costeffective alternatives, growing burden of chronic diseases, and growing aging population. Biosimilars are similar versions of their corresponding patented biologic drugs, a...

Schnell Biopharmaceuticals Inc 003060 Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummarySchnell Biopharmaceuticals Inc Schnell is a manufacturer of pharmaceutical products. The company provides pharmaceutical products including amino acid infusion agents and antibiotics. Its products portfolio includes antibiotics, infusions, containing amino acid, vitamin and hepatic protect infusions; gastrointestinal agents, comprising of digestives and antiulcerants; musculoskeletal system...

Navidea Biopharmaceuticals Inc NAVB Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryNavidea Biopharmaceuticals Inc Navidea, is a precision medicine company that focuses on the development and commercialization of radiopharmaceutical agents and precision diagnostics. The company by utilizing its Manocept platform develops multiple precisiontargeted products to identify pathways of undetected disease to provide better diagnostic accuracy, clinical decisionmaking and effectiv...

Sillajen Biotherapeutics Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummarySillajen Biotherapeutics SillaJen, formerly SillaJen, Inc. is a biotechnology company that designs and develops multifunctional immunotherapeutics for cancer. The company's first pipeline product PexaVec, is an oncolytic immunotherapeutic virus, administered intravenously, helps in triggering cancer targeting antibodies which combats against cancer cells. This is effective for treating hepa...

ASBM Statement on Final Guidance for Industry Nonproprietary Naming of Biological Products

ARLINGTON, Va., Jan. 13, 2017 /PRNewswire/ -- The Alliance for Safe Biologic Medicines (ASBM) today issued the following statement in response to FDA final guidance on biologic naming: We commend the FDA for its continued leadership in emphasizing the importance of distinct naming for all biologics, including biosimilars. Our members are keenly aware of the benefits biosimilars will bring...

Biosimilars applications under review by EMA – December 2016

The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars was established in 2003. Approval of biosimilars is based on an abbreviated registration process, which allows biosimilars manufacturers to provide a reduced package of information compared to originator drugs, provided they can prove ...

Eagle moves into biosimilars with Arsia acquisition

Specialty pharmaceuticals company Eagle Pharmaceuticals (Eagle) has signed an agreement to acquire Arsia Therapeutics (Arsia), the biotechnology company behind cutting-edge technology that enables intravenous drugs to be administered by injection.

RegeneRx Biopharmaceuticals Inc RGRX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryRegeneRx Biopharmaceuticals Inc RegeneRx is a biotechnology company that offers clinical stage drug development solutions. The company offers clinical trials, science and discovery and business development services. Its business development services include clinical development and commercialization interests in desired pharmaceutical therapeutic fields for suitable infrastructure, expertis...

Quick Search
Advertisement
 

review and buy Biotechnology Products market research data and corporate reports here